Richmond, VA Clinical Trials Report — June 2026

For Richmond residents considering participation in clinical research, June 2026 presents both urgent opportunities and promising new avenues to contribute to medical science. Across Richmond, VA, a significant number of trials are nearing their enrollment deadlines, making prompt action essential for interested individuals.

A total of 37 clinical trials are slated to conclude within the next 90 days. This urgency is particularly relevant for healthy volunteers, as 4 of these rapidly closing studies are still actively seeking participants without specific health conditions. These trials offer a chance to contribute to medical advancements before their enrollment windows close.

Impending Deadlines for Key Health Areas

Patients managing specific health conditions also face impending deadlines to join research. Trials focused on various conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Duchenne muscular dystrophy (2 trials)
• Kidney transplant; complications (2 trials)
• Parkinson's disease (2 trials)
• Alzheimer disease (1 trial)
• Attention-deficit/hyperactivity disorder (1 trial)
• BK virus infection (1 trial)
• Anthracycline related cardiotoxicity in breast cancer (1 trial)
• Breast cancer (1 trial)
• Bronchopulmonary dysplasia (1 trial)
• Care giving burden (1 trial)

New Research Opportunities Emerge

This month, Richmond saw the opening of 11 new clinical trials, an increase from the 6 trials that launched in May 2026. This marks the highest number of new trials in Richmond in the last six months, indicating a robust period of new research. This brings the total number of actively recruiting clinical trials in Richmond, VA, to 597 across 212 research facilities, underscoring the city's active research landscape.

June brings several high-profile new trials to Richmond, including significant Phase 2 and Phase 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Pfizer is initiating a notable Phase 3 study, NCT07629440, "A Study to Learn About How a New Pneumococcal Vaccine Works in Infants." This study aims for 3,230 participants to learn about the safety and immune response of a new pneumococcal vaccine in infants compared to existing options.
• Another Phase 3 study from Pfizer, NCT07660198, "Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents," seeks 1,200 participants. This research focuses on the safety and effectiveness of a new pneumococcal vaccine for children and adolescents.
• Novo Nordisk A/S is sponsoring NCT07668414, "A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide." This Phase 3 study aims for 650 participants to evaluate the safety and efficacy of zenagamtide for weight management.
• AstraZeneca is leading NCT07652658, "A Phase IIb Study to Evaluate AZD8965 in Participants With IPF." This Phase 2 study will involve 359 participants to assess the efficacy, safety, and tolerability of AZD8965 for Idiopathic Pulmonary Fibrosis (IPF).
• A unique study sponsored by Veterans Recovery Network Inc., NCT07661823, "QAIAx (AIhealth4U) - AI Public Health Central: Microcity-A," is a large-scale project aiming for 1,000,000 participants. It explores whether an "AI City Hall Project" can provide free or low-cost behavioral and mental health services within self-contained communities.
• Vanderbilt University Medical Center is sponsoring NCT07674758, "Modeling Mortality in Duchenne Muscular Dystrophy Cardiomyopathy: Identification of Surrogate Outcome Measures for DMD Drug Trials," which seeks 1,000 participants to better understand heart dysfunction in Duchenne and Becker Muscular Dystrophy.

New trials this month are exploring a range of conditions, with the most frequent being pneumococcal disease (2 trials) and obesity (2 trials). Other conditions include ADHD, alcohol abuse/dependence, alcohol addiction, alcohol and other drug use disorders, anger problems, breast cancer, ASD, and Asperger's disorder. Drug trials account for the largest share of new studies, with 5 new drug trials, followed by 2 biological trials, 2 device trials, 1 behavioral study, and 1 other type of study.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute to research. A total of 3 of the 11 new trials launched this month are actively seeking healthy volunteers. Across Richmond, a total of 46 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Richmond's Leading Research Facilities

Richmond is home to several leading research institutions and clinics that consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Virginia Commonwealth University (149 trials)
• VCU Massey Comprehensive Cancer Center (119 trials)
• VCU Massey Cancer Center at Stony Point (57 trials)
• Virginia Cancer Institute (26 trials)
• Bon Secours Saint Mary's Hospital (25 trials)
• Research Site (24 trials)
• Bon Secours Cancer Institute at Reynolds Crossing (21 trials)
• Bon Secours Richmond Community Hospital (14 trials)
• VCU Medical Center (11 trials)
• Clinical Research Partners, LLC (11 trials)
• Virginia Commonwealth University Massey Cancer Center (10 trials)
• Richmond VA Medical Center (9 trials)

These institutions offer a broad spectrum of research, with a strong focus on cancer research at the VCU Massey Comprehensive Cancer Center and its satellite locations, as well as general medical research at Virginia Commonwealth University and Bon Secours hospitals.

Broadening Your Search: Nearby Options

While Richmond offers a substantial array of clinical trial opportunities, individuals may also find options in nearby communities within Virginia. Cities with active trials include:

• Norfolk (5 trials)
• Charlottesville (4 trials)
• Newport News (3 trials)
• Roanoke (3 trials)
• Fairfax (3 trials)
• Lynchburg (2 trials)
• Suffolk (1 trial)
• Burke (1 trial)

Participation in clinical trials is open to a diverse range of individuals. Of the 11 new trials launched this month, 8 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 5 new trials include children, 1 is female-only, and 1 is male-only. Academic institutions like Virginia Commonwealth University (3 trials) and Vanderbilt University Medical Center (1 trial) continue to play a vital role in Richmond's research ecosystem, alongside industry sponsors such as Novo Nordisk A/S (2 trials), Pfizer (2 trials), and AstraZeneca (1 trial).

As we move through June, Richmond's dynamic research community will continue to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare.